TORONTO, ON, July 26, 2018 -- Easton Pharmaceuticals Inc. (OTC: EAPH) is pleased to announce that the Georgina property owned by its JV partner, 1124123 Ontario Limited (o/a – Alliance Group) resumes operations again, as of today Thursday, July 26th, 2018.
Easton’s JV partner, 1124123 Ontario Limited (o/a – Alliance Group) after delays resulting from various Municipal factors, resumes operations on its Georgina property, located just north of Toronto, Ontario, Canada.
Although one third of 2018Q3 has passed, Easton expects revenues from the Georgina property for the remaining Quarter to reach CAD $300,000 in revenues.
These operations mark the beginning of several businesses that will be carried out from the property. The first business is soil, while the company is gearing up for operations to soon commence from its aggregate business, with existing client orders.
Easton Pharmaceuticals and Alliance Group will be providing many more detailed updates in the coming weeks on revenue generation and future projections, which can now be booked on Easton’s financial statements.
Other updates will include information on new acquisitions and businesses that are currently being finalized, changes and new additions to its management team as well as a name change to better reflect the expansion of its business activities. The company intends on announcing its new 5 years business plan in the coming weeks.
Moreover, Easton is moving forward with audited financial statements and its retaining of an internationally recognized auditing firm now that revenues have re-commenced from its Georgina operations.
About Easton Pharmaceuticals
Easton Pharmaceuticals is a diversified specialty pharmaceutical company involved in various pharmaceutical sectors and other industries, which includes soil, aggregate, recycling, pharmaceuticals, diagnostic and other growing industries, such as real estate, hospitality, gaming, commodities, mining, transportation, maritime and marine services. The Company previously developed and owned an FDA-approved wound healing medical drug and currently owns topically delivered drugs to treat cancer and other therapeutic products to treat various conditions that are all in various stages of development and approval. Easton, through BMV Medica S.A., and together own the exclusive distribution rights in Mexico and Latin America for two patented women's diagnostic products and a novel natural treatment for Bacterial Vaginosis, which are to be distributed by Bayer. In addition, a generic cancer drug line is currently in the approval process for sale in Mexico. The company's gel formulation is thought to be an innovative and unique transdermal delivery system.
For More Information On Easton and Affiliated and Partner Companies Visit:
http://www.eastonpharmaceuticalsinc.com
http://finance.yahoo.com/q?s=eaph
https://twitter.com/eastonpharma
Safe Harbor
This news release may contain forward-looking statements or expressions within the meaning of the Private Securities Litigation Reform Act of 1995 (The "Act"). In particular, when certain words or phrases such as "hope", "positive", "anticipate," "pleased," "plan," "confident that," "believe," "expect," "possible" or "intent to" and similar conditional expressions are expressed, they are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Any investment made into Easton Pharmaceuticals may contain risks. Such risks and uncertainties include, but are not limited to, market conditions, general acceptance of the company's products and technologies, competitive factors, the ability to successfully complete additional or adequate financing, government approvals or changes to proposed laws and other risks and uncertainties further stated in the company's financial reports and filings.
Contact: Investor Relations
Tel: +1(416) 619-0291
Tel: +1(347) 284-0192
Email: eastonpharma@protonmail.com